- PA5-27322 - Invitrogen Antibodies VHL antibody

Submitted references Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1α (Hypoxia-Inducible Factor-1α) Pathway in Endothelial Cells.

Fernandez Esmerats J, Villa-Roel N, Kumar S, Gu L, Salim MT, Ohh M, Taylor WR, Nerem RM, Yoganathan AP, Jo H
Arteriosclerosis, thrombosis, and vascular biology 2019 Mar;39(3):467-481

miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.

Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ
Nature metabolism 2019 Apr;1(4):460-474

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of VHL using A) 30 µg Neuro2A whole cell lysate and B) 30 µg GL261 whole cell lysate. Samples were loaded onto a 12% SDS-PAGE gel and probed with a VHL polyclonal antibody (Product # PA5-27322) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of VHL using 30 µg of MOLT4 lysate. Samples were loaded onto a 12% SDS-PAGE gel and probed with a VHL polyclonal antibody (Product # PA5-27322) at a dilution of 1:2000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot analysis of VHL was performed by separating 30 µg of non-transfected (–) and transfected (+) 293T whole cell extracts by 12% SDS-PAGE. Proteins were transferred to a membrane and probed with a VHL Polyclonal Antibody (Product # PA5-27322) at a dilution of 1:5000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using VHL Polyclonal Antibody (Product # PA5-27322). Various whole cell extracts (30 µg) were separated by 12% SDS-PAGE, and the membrane was blotted with VHL Polyclonal Antibody (Product # PA5-27322) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot analysis of VHL was performed by separating 30 µg of various whole cell extracts by 12% SDS-PAGE. Proteins were transferred to a membrane and probed with a VHL Polyclonal Antibody (Product # PA5-27322) at a dilution of 1:1000 and a HRP-conjugated anti-rabbit IgG secondary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry-Immunofluorescence analysis of VHL was performed in HeLa cells fixed in 4% paraformaldehyde at RT for 15 min. Green: VHL Polyclonal Antibody (Product # PA5-27322) diluted at 1:500. Red: phalloidin, a cytoskeleton marker. Scale bar = 10 µm.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of VHL was performed in paraffin-embedded mouse lung tissue using VHL Polyclonal Antibody (Product # PA5-27322) at a dilution of 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of VHL was performed in paraffin-embedded mouse kidney tissue using VHL Polyclonal Antibody (Product # PA5-27322) at a dilution of 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 miR-147b-VHL axis mediates drug-tolerance through impaired VHL activity. a , Left, gene candidates predicted for miR-147b by the TargetScan tool were shown in signaling pathways enriched for gefitinib-tolerance in PC9 single-cell clones in fig. 1f . Right, qRT-PCR analysis for the predicted gene candidates for miR-147b in H1975 cells with miR-147b knockdown compared with scrambled control. n=3 independent biological replicates. b , Left, computational prediction of RNA duplex formation between miR-147b and the 3'UTR (untranslated region) of VHL mRNA. Mutations generated within the 3'UTR for the luciferase assay are shown in red. Right, dual-luciferase reporter assay in miR-147b-overexpressing AALE cells. The Firefly luciferase and Renilla luciferase activities were measured 48 hours post co-transfection with miR-147b or control vector and wild-type (WT) or mutant (Mut) VHL 3'UTR. n=3 independent biological replicates. c , Western blot analysis and quantification of VHL in miR-147b-overexpressing AALE cells. beta-Actin was used as loading control. n=3 independent biological replicates. d , qRT-PCR analysis for fold change of hypoxia gene expression in AALE cells with miR-147b overexpression relative to scrambled control (147b/Scr) and cells with co-overexpression of miR-147b and VHL relative to scrambled control (147b+VHL/Scr). ACTB was used as endogenous control. n=3 independent biological replicates. e , Fractional viability of HCC827 cells treated with vehicle, osi

PA5-27322

Antibody data